Chapter 16 Antibody-mediated disorders of neuromuscular transmission

Supplements to Clinical Neurophysiology

Volumn 57, Issue C, 2004, Pages 147-158

  Vincent, Angela ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHOLINERGIC RECEPTOR; SEROTONIN;

ANIMAL; BIOLOGICAL MODEL; EATON LAMBERT SYNDROME; HUMAN; IMMUNOLOGY; METABOLISM; MYASTHENIA GRAVIS; MYOKYMIA; NEUROMUSCULAR JUNCTION DISORDER; NEUROMUSCULAR SYNAPSE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SYNAPTIC TRANSMISSION;

ANIMALS; ANTIBODIES; HUMANS; ISAACS SYNDROME; LAMBERT-EATON MYASTHENIC SYNDROME; MODELS, NEUROLOGICAL; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR JUNCTION DISEASES; RECEPTORS, CHOLINERGIC; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 25144435451     PISSN: 1567424X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1567-424X(09)70352-6     Document Type: Article

References (76)

1. Aarli J.A. Titin, thymoma, and myasthenia gravis. Arch. Neurol. 58 (2001) 869-870
2. + channel antibodies. Neurology 54 (2000) 771-772
3. Barrett-Jolley R., Byrne N., Vincent A., and Newsom-Davis J. Plasma from patients with seronegative myasthenia gravis inhibit nAChR responses in the TE671/RD cell line. Pflugers Arch. 428 (1994) 492-498
4. Blaes F., Beeson D., Plested P., et al. IgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor. Ann. Neurol. 47 (2000) 504-510
5. Buckley C., Newsom-Davis J., Willcox N., and Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?. Neurology 57 (2001) 1579-1582
6. Bufler J., Pitz R., Czep M., et al. Purified IgG from seropositive and seronegative patients with myasthenia gravis reversibly blocks currents through nicotinic acetylcholine receptor channels. Ann. Neurol. 43 (1998) 458-464
7. Barges J., Wray D.W., Pizzighella S., et al. A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro. Muscle Nerve 13 (1990) 407-413
8. Burges J., Vincent A., Molenaar P.C., et al. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 17 (1994) 1393-1400
9. Clouston P.D., Saper C.B., Arbizu T., et al. Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurology 42 (1992) 1944-1950
10. Compston D.A., Vincent A., Newsom-Davis J., and Batchelor J.R. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103 (1980) 579-601
11. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 330 (1994) 1797-1810
12. Drachman D.B., Angus C.W., Adams R.N., and Kao I. Effect of myasthenic patients' immunoglobulin on acetylcholine receptor turnover: selectivity of degradation process. Proc. Natl. Acad. Sci. USA 75 (1978) 3422-3426
13. Drachman D.B., Angus C.W., Adams R.N., et al. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N. Engl. J. Med. 298 (1978) 1116-1122
14. Engel A.G. Review of evidence for loss of motor nerve terminal calcium channels in Lambert-Eaton myasthenic syndrome. Ann. N.Y. Acad. Sci. 635 (1991) 246-258
15. Engel A.G., and Arahata K. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann. N.Y. Acad. Sci. 505 (1987) 326-332
16. Engel A.G., Lambert E.H., and Howard F.M. Immune complexes (IgG and C3) at the motor endplate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin. Proc. 52 (1977) 267-280
17. Evoli A., Batocchi A.P., Lo Monaco M., et al. Clinical heterogeneity of seronegative myasthenia gravis. Neuromuscul. Disord. 6 (1996) 155-161
18. Evoli, A., Tonali, P.A. and Padua, L. et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain, 2003.
19. Giovannini F., Sher E., Webster R., et al. Calcium channel subtypes contributing to a acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodies-affected neuromuscular junctions. Br. J. Pharmacol. 136 (2002) 1135-1145
20. Graus F., Lang B., Pozo-Rosich P., et al. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 59 (2002) 764-766
21. Halbach M., Homberg V., and Freund H.J. Neuromuscular, autonomic and central cholinergic hyperactivity associated with thymoma and acetylcholine receptor-binding antibody. J, Neurol. 234 (1987) 433-436
22. Hall Z.W., and Sanes J.R. Synaptic structure and development: the neuromuscular junction. Cell 72 Suppl. (1993) 99-121
23. + channels are implicated in neuromyotonia. Ann. Neurol. 41 (1997) 238-246
24. Hart I.K., Maddison P., Newsom-Davis J., et al. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 125 (2002) 1887-1895
25. Harvey A.L. Presynaptic effects of toxins. Int. Rev. Neurobiol. 32 (1990) 201-239
26. Hoch W., McConville J., Helms S., et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7 (2001) 365-368
27. Kaminski H.J., Kusner L.L., and Block C.H. Expression of acetylcholine receptor isoforms at extraocular muscle end-plates. Invest. Ophthalmol. Vis. Sci. 37 (1996) 345-351
28. Kaminski H.J., Richmonds C.R., Kusner L.L., and Mitsumoto H. Differential susceptibility of the ocular motor system to disease. Ann. N. Y. Acad. Sci. 956 (2002) 42-54
29. Kim Y.I. Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG. Muscle Nerve 9 (1986) 523-530
30. Lang B., Newsom-Davis J., Prior C., and Wray D. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. J. Physiol. 344 (1983) 335-345
31. + flux into TE671 cell line. J. Neuroimmunol. 19 (1988) 141-148
32. Lee E.K., Maselli R.A., Ellis W.G., and Agius M.A. Morvan's fibrillary chorea: a paraneoplastic manifestation of thymoma. J. Neurol. Neurosurg. Psychiatry 65 (1998) 857-862
33. Lennon V.A., Kryzer T.J., Griesmann G.E., et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N. Engl. J. Med. 332 (1995) 1467-1474
34. Liguori R., Vincent A., Clover L., et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124 (2001) 2417-2426
35. Liyanage Y., Hoch W., Beeson D., and Vincent A. The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 25 (2002) 4-16
36. McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., and Vincent A. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann. Neurol. 55 (2004) 580-584
37. Meager A., Wadhwa M., Bird C., et al. Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease. Immunology 97 (1999) 526-532S
38. Mossman S., Vincent A., and Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet I (1986) 116-119
39. Motomura M., Johnston I., Lang B., et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J. Neurol. Neurosurg. Psychiatry 58 (1995) 85-87
40. Motomura M. (The Lambert-Eaton myasthenic syndrome: a study of 110 Japanese cases). Rinsho Shinkeigaku 39 (1999) 1237-1239
41. Mygland A., Tysnes O.B., Matre R., et al. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann. Neurol. 32 (1992) 589-591
42. Nemoto, Y., Kuwabara, S., Kawaguchi, N., Vincent, A. and Hattori, T. Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. Muscle Nerve, pending resubmission.
43. Newsom-Davis J., and Mills K.R. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain 116 (1993) 453-469 Pt. 2
44. Newsom-Davis J., Pinching A.J., Vincent A., and Wilson S.G. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology 28 (1978) 266-272
45. O'Neill J.H., Murray N.M., and Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111 (1988) 577-596 Pt. 3
46. Pinto A., Gillard S., Moss F., et al. Human autoantibodies specific for the alpha 1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc. Natl. Acad. Sci. USA 95 (1998) 8328-8333
47. Plested C.P., Tang T., Spreadbury I., et al. AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology 59 (2002) 1682-1688
48. Plomp J.J., Van Kempen G.T., De Baets M.B., et al. Acetylcholine release in myasthenia gravis: regulation at single end-plate level. Ann. Neurol. 37 (1995) 627-636
49. Poea S., Guyon T., Bidault J., et al. Modulation of acetylcholine receptor expression in seronegative myasthenia gravis. Ann. Neurol. 48 (2000) 696-705
50. Poulas K., Tsibri E., Kokla A., et al. Epidemiology of seropositive myasthenia gravis in Greece. J. Neurol. Neurosurg. Psychiatry 71 (2001) 352-356
51. Protti D.A., and Uchitel O.D. P/Q-type calcium channels activate neighboring calcium-dependent potassium channels in mouse motor nerve terminals. Pflugers Arch. 434 (1997) 406-412
52. Riemersma S., Vincent A., Beeson D., et al. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J. Clin. Invest. 98 (1996) 2358-2363
53. Robertson N.P., Deans J., and Compston D.A. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J. Neurol. Neurosurg. Psychiatry 65 (1998) 492-496
54. Ruff R.L., and Lennon V.A. End-plate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis. Ann. Neurol. 43 (1998) 370-379
55. Sanders D.B., El-Salem K., Massey J.M., et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60 (2003) 1978-1980
56. Seuderi F., Marino M., Colonna L., et al. Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab. Invest. 82 (2002) 1139-1146
57. Senanayake N., and Roman G.C. Disorders of neuromuscular transmission due to natural environmental toxins. J. Neurol. Sci. 107 (1992) 1-13
58. + channels of peripheral nerves. Ann. Neurol. 38 (1995) 714-722
59. Sinha S., Newsom-Davis J., Mills K., et al. Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet 338 (1991) 75-77
60. Somnier F.E., and Engel P.J. The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970-1999. Neurology 59 (2002) 92-98
61. Takamori M., Komai K., and Iwasa K. Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome. Am. J. Med. Sci. 319 (2000) 204-208
62. Toyka K.V., Brachman D.B., Pestronk A., and Kao I. Myasthenia gravis: passive transfer from man to mouse. Science 190 (1975) 397-399
63. 2+ channels. Trends Pharmacol. Sci. 12 (1991) 349-354
64. Verma P.K., and Oger J.J. Seronegative generalized myasthenia gravis: low frequency of thymic pathology. Neurology 42 (1992) 586-589
65. Vincent A. Understanding neuromyotonia. Muscle Nerve 23 (2000) 655-657
66. Vincent A., Li Z., Hart A., et al. Seronegative myasthenia gravis. Evidence for plasma factor(s) interfering with acetylcholine receptor function. Ann. N.Y. Acad. Sci. 681 (1993) 529-538
67. Vincent A., Palace J., and Hilton-Jones D. Myasthenia gravis. Lancet 357 (2001) 2122-2128
68. Vincent A., Bowen J., Newsom-Davis J., and McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol. 2 (2002) 99-106
69. Vincent A., Clover L., Buckley C., et al. Evidence of underdiagnosis of myasthenia gravis in older people. J. Neurol. Neurosurg. Psychiatry 74 (2003) 1105-1108
70. Waterman S.A. Multiple subtypes of voltage-gated calcium channel mediate transmitter release from parasympathetic neurons in the mouse bladder. J. Neurosci. 16 (1996) 4155-4161
71. Waterman S.A., Lang B., and Newsom-Davis J. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse. Ann. Neurol. 42 (1997) 147-156
72. Willcox N., Schluep M., Ritter M.A., and Newsom-Davis J. The thymus in seronegative myasthenia gravis patients. J. Neurol. 238 (1991) 256-261
73. Wirtz P.W., Roep B.O., Schreuder G.M., et al. HLA class I and II in Lambert-Eaton myasthenic syndrome without associated tumor. Hum. Immunol. 62 (2001) 809-813
74. Wirtz P.W., Sotodeh M., Nijnuis M., et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J. Neurol. Neurosurg. Psychiatry 73 (2002) 766-768
75. Zhou L., McConville J., Chaudhry V., Adams R.N., Skolasky R.L., Vincent A., and Drachman D.B. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 30 (2004) 55-60
76. Yamamoto T., Vincent A., Ciulla T.A., et al. Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM. Ann. Neurol. 30 (1991) 550-557